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ampReduced-intensity conditioning (RIC) extends the curative potential of allogeneic hematopoietic cell trans-
plantation (HCT) to patients with hematologic malignancies unable to withstand myeloablative conditioning.
We prospectively analyzed the outcomes of 123 patients (median age, 57 years; range, 23-70 years) with he-
matologic malignancies treated with a uniform RIC regimen of cyclophosphamide, fludarabine, and total-
body irradiation (200 cGy) with or without antithymocyte globulin followed by related donor allogeneic
HCT at the University of Minnesota between 2002 and 2008. The cohort included 45 patients with acute
myelogenous leukemia (AML) or myelodysplastic syndrome (MDS), 27 with aggressive non-Hodgkin lym-
phoma (NHL), 8 with indolent NHL, 10 with Hodgkin lymphoma (HL), 10 with myeloma, and 23 with acute
lymphocytic leukemia, chronic myelogenous leukemia, other leukemias, or myeloproliferative disorders. The
probability of 4-year overall survival was 73% for patients with indolent NHL, 58% for those with aggressive
NHL, 67% for those with HL, 30% for those with AML/MDS, and only 10% for those with myeloma. Corres-
ponding outcomes for relapse in these patients were 0%, 32%, 50%, 33%, and 38%, and those for progression-
free survival were 73%, 45%, 27%, 27%, and 10%. The incidence of treatment-related mortality was 14% at
day 1100 and 22% at 1 year. The incidence of grade II-IV acute graft-versus-host disease was 38% at day
1100, and that of chronic graft-versus-host disease was 50% at 2 years. Multivariate analysis revealed
superior overall survival and progression-free survival in patients with both indolent and aggressive NHL
compared with those with AML/MDS, HL, or myeloma. Worse 1-year treatment-related mortality was
observed in patients with a Hematopoietic Cell Transplantation Comorbidity Index score $3 and in
cytomegalovirus-seropositive recipients. These results suggest that (1) RIC conditioning was well tolerated
by an older, heavily pretreated population; (2) patients with indolent and aggressive NHL respond well to
RIC conditioning, highlighting the importance of the graft-versus-lymphoma effect; and (3) additional peri-
transplantation manipulations are needed to improve outcomes for patients with AML/MDS or myeloma
receiving RIC conditioning before HCT.
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Allogeneic hematopoietic cell transplantation
(HCT) is standard therapy for a wide range of hemato-
logic malignancies. Advanced age, medical comorbid-
ities, and previous treatment history can preclude the
use of more toxic myeloablative conditioning and limit
the applicability of this potentially curative therapy.
Consequently, reduced-intensity conditioning (RIC)
regimens have been developed to limit transplantation-
related mortality (TRM) and broaden the use of HCT.
RIC regimens have the added benefits of shorter dura-
tion of neutropenia and thrombocytopenia, decreased
hospitalization time, and potential improvements in
long-term survival due to decreased TRM. Previous
studies have suggested that outcomes with RIC are af-
fected by underlying disease type, disease stage at trans-
plantation, comorbidity, and the degree of reduced
conditioning intensity [1-8].
We report here on our experience with a consistent
RIC platform of cyclophosphamide, fludarabine, and
low-dose total-body irradiation (TBI), evaluating en-
graftment and toxicity, and present multiyear follow-
up to assess risk of late relapse and long-term survival.PATIENTS AND METHODS
Patients and Inclusion Criteria
All consecutive adult patients (age range, 18-70
years) undergoing RIC allogeneic HCT from adult re-
lated donors at the University of Minnesota between
2002 and 2008 were enrolled on this single-center trial
and included in the analysis. Disease eligibility criteria
included the following: (1) acutemyelogenous leukemia
(AML), high-risk complete remission (CR) 1 or CR2 or
greater; (2) acute lymphoblastic leukemia (ALL), high-
risk CR1 or CR2 or greater; (3) chronic myelogenous
leukemia (CML), all phases except blast crisis; (4)
non-Hodgkin lymphoma (NHL), Hodgkin lymphoma
(HL), chronic lymphocytic leukemia or myeloma dem-
onstrating chemosensitive disease; (5) myelodysplastic
syndrome (MDS) of all subtypes, with severe pancyto-
penia or transfusion-dependency and blasts \ 5%;
and (6) chronic myeloproliferative disorders.
To be eligible for this analysis, patients had to be
aged#70 years with an HLA 5/6 or 6/6 related donor
match. Younger patients were enrolled on myeloabla-
tive protocols when possible but were eligible if they
had evidence of organ dysfunction, were heavily pre-
treated, or had a recent fungal infection, as described
previously [9]. Minimum required organ function
was cardiac ejection fraction $35%, no decompen-
sated heart failure or uncontrolled arrhythmia, CO
diffusing capacity $30% predicted, no oxygen re-
quirement, serum transaminases \5 upper limit of
normal, serum bilirubin \3 upper limit of normal,serum creatinine #2 mg/dL or creatinine clearance
.40 mL/min, Karnofsky performance status (KPS)
.60, mold infections treated and responding after
a minimum of 30 days of therapy, and serum albumin
.2.5 g/dL. Patients with an active serious infection,
previous TBI precluding the use of 200 cGy of TBI,
CML in refractory blast crisis, or chemoresistant lym-
phoma or myeloma were not eligible for enrollment in
this trial.
Disease status at the time of transplantation was
defined as early (CR1, refractory anemia, refractory
anemia with ringed sideroblasts, CML chronic phase),
intermediate (CR2, partial remission 1, refractory
anemia with excess blasts), or advanced (CR3 or
greater, partial remission 2 or greater, primary induc-
tion failure, minimally responsive or stable disease).
Hematopoietic Cell Transplantation Comorbidity
Index (HCT-CI) scores were calculated and assigned
retrospectively.
Related Donor Grafts
Peripheral blood stem cells (PBSCs) were collected
after priming with granulocyte-colony stimulating
factor 10 mg/kg s.c. daily for 5 days. Donors were
collected for 1-3 days with a target CD341 cell dose
of 5  106 CD341 cells per kg of recipient weight.
Donors who failed to collect the minimum required
cell dose of 2  106 CD341 cells/kg underwent bone
marrow harvest, with a target nucleated cell dose of
3 108 per kg recipient weight. Grafts were not mani-
pulated and were infused by gravity without line
filtration after premedication with acetaminophen
and diphenhydramine. Patients receiving ABO-
incompatible grafts also received pretransplantation
and posttransplantation hydration and red blood cell
or plasma depletion as indicated.
Treatment Regimen
Conditioning for all patients consisted of fludara-
bine 40 mg/m2 i.v. on day -6 through day -2 for a total
dose of 200 mg/m2 (reduced to 30 mg/m2/day for
those with limited renal function, defined as raw creat-
inine clearance\70 mg/min/m2, and those with previ-
ous cranial radiation), cyclophosphamide 50mg/kg i.v.
on day -6, and a single 200-cGy dose of TBI on day -1.
Equine antithymocyte globulin (ATG), 15 mg/kg i.v.
every 12 hours for 6 doses on days -6, -5, and -4 with
methylprednisolone 1 mg/kg, was administered to
those not exposed to combination chemotherapy
within the preceding 6 months.
Graft-versus-host disease (GVHD) prophylaxis
consisted of cyclosporine, targeting a trough level of
200-400 ng/mL, and mycophenolate mofetil (MMF)
2-3 g/day, from day -3 up to day 130. Cyclosporine
was continued through day 1100 and if no evidence
of GVHD was seen, was then tapered at a rate of
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5 mg/kg was administered beginning on day 11 and
continued until the absolute neutrophil count (ANC)
was .2.5  109/L for 2 consecutive days. Infectious
prophylaxis was directed to include antibacterial,
antifungal, and antiviral therapies in accordance with
institutional guidelines.Study Endpoints
This study’s primary clinical endpoint was engraft-
ment. Successful sustained engraftment was defined as
primary neutrophil recovery by day 142 and 90%
donor cells at day1100. Additional endpoints for anal-
ysis were overall survival (OS), TRM, relapse, progres-
sion-free survival (PFS), donor engraftment, acute
GVHD (aGVHD), and chronic GVHD (cGVHD).
Safety endpoints were included, defined as the de-
velopment of severe adverse events totaling $30%
TRM at day1100. There was continuous monitoring
for stopping rules for TRM by day 1100. In brief,
early termination of the study was defined to occur if
the following number of TRM deaths occurred before
day 1100: 3 of 4, 4 of 6, 5 of 8, 6 of 11, 7 of 13,
8 of 16, and so on, with a type I error rate of 0.05,
for a rate of 30% and power of 80% to detect a rate
of 50%.
Measures of engraftment included neutrophil re-
covery to an ANC of 0.5  109/L for 3 consecutive
days and 7 days of untransfused platelet recovery
.20  109/L. Diagnoses of aGVHD and cGVHD
were based on standard clinical criteria, with histo-
pathological confirmation where possible [10,11].
Diagnosis of relapse was based on hematologic,
morphologic, and cytogenetic or molecular evaluation.
Probabilities of OS and PFS were estimated by the
Kaplan-Meier method [12]. Cumulative incidence
rates and 95% confidence intervals (CIs) were esti-
mated for neutrophil engraftment, relapse, TRM,
and GVHD. Non-event deaths (or relapse for TRM)
were defined as competing risks [13]. The variables
of age, sex, CD341 cell dose, KPS $90, HCT-CI
(0-2 vs 31), cytomegalovirus (CMV) serostatus, dis-
ease group, and ATG exposure were considered in
multivariate analysis. Statistical comparison of time-to-
event curves was completed using a log-rank test.
Stem cell and donor source were not included as a vari-
able in multivariate analysis, because nearly all were
PBSCs from 6/6 HLA-matched related donors. Previ-
ous transplantation was not included in multivariate
analysis because the majority were autologous trans-
plantations for lymphoma and a surrogate marker of
disease type, and disease stagewas not included because
of the heterogeneity of diseases and stages at transplan-
tation in our cohort.
Cox regression was used for engraftment, survival,
and PFS, and the method of Fine and Gray was used inmultivariate regression for the competing-risk end-
points relapse, TRM, andGVHD [14]. Final multivar-
iate models were selected by a backward-stepwise
method using variables with P 5 .20 retained in the
model. Because of the small numbers of patients with
ALL, myeloproliferative disorders, CML, and ‘‘other
leukemias,’’ these subsets were not included in multi-
variate analysis.
Statistical analyses were performed using SAS 9.2
(SAS Institute, Cary, NC). All P values were two-
sided. Groups with P values of #.05 were considered
statistically different.
This trial was a prospective clinical study that was
reviewed and approved by the Masonic Cancer Cen-
ter Protocol Review Committee and Human Subjects
Institutional Review Board at the University of Min-
nesota. All patients provided Institutional Review
Board–approved informed consent in accordance
with the Declaration of Helsinki. The trial was regis-
tered at ClinicalTrials.gov (NCT00303719).RESULTS
Patients
The study cohort comprised 123 consecutive pa-
tients (65% males; median age, 57 years; range, 23-
70 years) who underwent allogeneic related RIC
HCT for hematologic malignancies (Table 1). AML/
MDS (37%) and aggressive NHL (22%) were the
most prevalent malignancies; others included indolent
lymphomas, HL, myeloma, chronic leukemias, myelo-
proliferative disorders, and ALL. The median time
from diagnosis to HCT was 24 months (range, 2.5-
154), and the median duration of follow-up was 2.5
years (range, 0.3-6.6 years). An HCT-CI of 0-2 was
seen in 47% of the patients; an HCT-CI 31 was
seen in a majority of the patients who otherwise would
have qualified for myeloablative conditioning based on
age. Fourteen percent had a previous HCT (3 alloge-
neic, 14 autologous); PBSCs were used in 96%, 92%
had a matched related donor (6/6 HLA-matched),
and 8% had a mismatched related donor (5/6 HLA-
matched).Engraftment
All patients achieved neutrophil recovery by day
142, with a median time to ANC recovery of 8 days
(range, 0-15 days). Seventy-five percent (95% CI,
67%-82%) had platelet recovery by day 42, at amedian
of 16.5 days (range, 0-37 days). At day 1100, 110 pa-
tients (89.4%) had .90% donor chimerism in the
marrow. One patient lost donor engraftment at day
309 with no evidence of recurrent small lymphocytic
lymphoma but with marrow morphology and chime-
rism studies demonstrating recipient-derived MDS.
Table 1. Patient Characteristics
Total number of patients 123
Age at treatment, years, median (range) 57 (23-70)
Age group at treatment, years, n (%)
<40 10 (8)
40-49 19 (15)
50-59 55 (45)
$60 39 (32)
Sex, n (%)
Male 80 (65)
Female 43 (35)
Previous HCT, n (%)
No 106 (86)
Yes 17 (14)
Allogeneic 3 (18)
Autologous 14 (82)
Disease group and disease status at HCT, n (%)*
AML/MDS (early, n 5 21; intermediate,
n 5 14; advanced, n 5 10)
45 (37)
Aggressive NHL (early, n 5 2; intermediate,
n 5 2; advanced, n 5 23)
27 (22)
Indolent NHL (early, n 5 1; advanced, n 5 7) 8 (7)
HL, advanced 10 (8)
Myeloma (intermediate, n 5 3; advanced,
n 5 7)
10 (8)
Other (early, n 5 3; intermediate,
n 5 16; advanced, n 5 4)
23 (18)
Time from diagnosis to HCT, months,
median (range)
23.6 (2.5-154)
HCT-CI score, n (%)
0 20 (16)
1-2 38 (31)
3+ 65 (53)
CD34+ cells  106/kg, median (range) 5.79 (0.64-21.84)
ATG use in conditioning, n (%)
No 93 (76)
Yes 30 (24)
Recipient CMV status, n (%)
Negative 55 (45)
Positive 68 (55)
CMV status, n (%)
D-R- 38 (31)
D+R- 17 (14)
D-R+ 32 (26)
D+R+ 36 (29)
Year of HCT, n (%)
2002-2003 34 (27.5)
2004-2005 35 (28.5)
2006-2008 54 (44)
Cell source, n (%)
Bone marrow† 5 (4)
PBSCs 118 (96)
HLA matching, n (%)‡
Matched related (6/6) 113 (92)
Mismatched related(5/6) 10 (8)
Follow-up of survivors, months, median (range) 30.6 (3.3-81)
HCT indicates hematopoietic cell transplantation; D, donor; R, recipient;
M, marrow; AML, acute myelogenous leukemia; MDS, myelodysplastic
syndrome; NHL, non-Hodgkin lymphoma; P, peripheral blood.
*Disease groups:
 AML (n 5 33) and MDS (n 5 12)
Aggressive lymphoma: diffuse large cell (n5 10), other aggressiveNHL
(n 5 12), mantle (n 5 4), Burkitt (n 5 1)
 Other: ‘‘other leukemia’’ (n 5 10), CML (n5 4), ALL (n5 3), myelo-
proliferative disease (n 5 6)
†Four of the 5 patients with a bone marrow source had both bone mar-
row and PBSCs because they did not adequately collect peripherally and
required bone marrow harvest to achieve the minimum cell dose.
‡HLA matching:
 Matched related includes sibling with 6/6 or 8/8 match (n 5112) and
cousin with 6/6 match (n 5 1).
 Related mismatch includes sibling with 5/6 match (n5 9) and offspring
mismatched (5/6) (n 5 1).
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OS
At a median follow-up of 2.5 years (range, 0.3-6.75
years), 64 patients survived, for a 4-year OS of 45%
(95% CI, 35%-55%). The underlying diagnosis had
a significant affect on OS, with the best survival seen
in those with indolent NHL (73%; 95% CI, 28%-
93%), HL (67%; 95% CI, 27%-88%), or aggressive
NHL (58%; 95%CI, 34%-77%) compared with those
with AML/MDS (30%; 95% CI, 14%-47%), or mye-
loma (10%; 95%CI, 1%-36%) (P# .01) (Figure 1 and
Table 2).
In multivariate analysis, only disease group signif-
icantly affected OS. Compared with patients with
AML/MDS, survival was better in patients with
aggressive NHL (relative risk [RR], 0.41; 95% CI,
0.19-0.89), indolent NHL (RR 0.25; 95% CI, 0.06-
1.09), and HL (RR, 0.32; 95% CI, 0.09-1.06) and
considerably worse in those with myeloma (RR, 1.69;
95% CI, 0.78-3.65) (P\ .01). Interestingly, age and
HCT-CI had no impact on OS (Table 3).
PFS
The 4-year PFS for the entire cohort was 29%
(95% CI, 20%-38%). Underlying diagnosis was the
only feature that significantly affected PFS. Patients
with indolent and aggressive NHL had the best 4-
year PFS, at 73% (95% CI, 28%-93%) and 45%
(95% CI, 21%-66%), respectively (P 5 .02). In con-
trast, 4-year PFS was only 27% (95% CI, 5%-56%)
for patients those with HL, 27% (95% CI, 13%-
44%) for those with AML/MDS, and 10% (95% CI,
1%-36%) for those with myeloma (Table 2).
The impact of disease type on 4-year PFS was sub-
stantiated in multivariate analysis. Compared with
AML/MDS, outcomes were better in indolent and ag-
gressive NHL (RR, 0.26 [95% CI, 0.06-1.10] and 0.49
[95% CI, 0.25-0.97], respectively) and worse in mye-
loma (RR, 1.87; 95%CI, 0.87-4.02) (P5 .02).Noother
factors in the multivariate analysis had a significant
impact on PFS.
Relapse
The 4-year cumulative incidence of relapse for the
entire cohort was 36% (95% CI, 25-47%). In univari-
ate analysis, the relapse rate varied depending on the
underlying disease. Notably, no patients with indolent
NHL relapsed. Patients with AML/MDS, aggressive
NHL, and myeloma had similar rates of relapse:
33% (95% CI, 17%-49%), 32% (95% CI, 9%-54%),
and 38% (95% CI, 7%-69%), respectively (P 5 .12).
The majority of relapses in patients with AML/MDS
and myeloma occurred within the first year, whereas
relapses occurred out to 3-4 years in patients with
aggressive NHL. Patients with HL had the highest
Figure 1. Four-year OS by disease group.
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all relapses occurring within the first year (Figure 2).
Multivariate analysis for relapse at 4 years showed no
significantly different outcomes based on disease
group or any other variable tested, likely related to
the timing of relapse within each disease group.
TRM
Day 1100 TRM for the entire cohort was 14%
(95% CI, 8%-20%). In univariate analysis, day 1100
TRM was 7% (95% CI, 0-13%) for patients with an
HCT-CI of 0-2 and 20% (95% CI, 10%-30%) for
those with an HCT-CI of 31 (P 5 .04). One-year
TRMwas 22% (95% CI, 14%-29%) for the entire co-
hort, 13% (95% CI, 2%-25%) for patients with an
HCT-CI of 0-2, and 29% (95% CI, 17%-40%) for
those with an HCT-CI of 31 (P 5 .04) (Figure 3).
One-year TRM was only 13% (95% CI, 4%-22%)
for CMV-seronegative recipients, compared with
29% (95% CI, 17%-41%) in CMV-seropositive
recipients (P 5 .04).
In multivariate analysis, TRM at 1 year was signif-
icantly affected by recipient CMV serologic status
(RR, 2.71; 95% CI, 1.08-6.79; P 5 .03 in CMV-
seropositive recipients) and by HCT-CI (RR, 2.41;
95% CI, 1.02-5.70; P 5 .04) in patients with an
HCT-CI of 31). Age, sex, CD341 cell dose, KPS,
ATG exposure, and disease type were included as fac-
tors in the multivariate analysis and found to have no
significant impact on outcomes (Table 3).Table 2. One-Year and 4-Year Univariate Outcomes by Disease Gr
Disease Group
OS, % (95% CI) PFS, %
1-Year 4-Year 1-Year
Indolent NHL (n 5 8) 88 (39-98) 73 (28-93) 88 (39-98)
Aggressive NHL (n 5 27) 81 (60-92) 58 (34-77) 70 (49-84)
HL (n 5 10) 80 (41-95) 67 (27-88) 40 (12-67)
AML + MDS (n 5 45) 51 (35-65) 30 (14-47) 40 (26-55)
Myeloma (n 5 10) 40 (12-67) 10 (1-36) 20 (3-47)
NHL indicates non-Hodgkin lymphoma; HL, Hodgkin lymphoma; AML, acute m
free survival; OS, overall survival; CI, confidence interval.GVHD
At 100 days, the cumulative incidence of aGVHD
was 38% (95% CI, 29%-47%) for grade II-IV and
20% (95% CI, 13%-27%) for grade III-IV. Rates of
day 1100 aGVHD grade II-IV were decreased in
more recent years, with an incidence of only 24%
(95% CI, 13%-36%) in 2006-2008 versus that of
52% (95% CI, 33%-70%) in 2002-2003 (P 5 .05).
ATG use increased in the latter years; only 6% (n 5
2) of patients received ATG in 2002-2003, compared
with 31% (n 5 11) in 2004-2005 and 31% (n 5 17)
in 2006-2008. The 6-month cumulative incidence of
aGVHD was 47% (95% CI, 37%-56%) for grade II-
IV and 26% (95% CI, 18%-34%) for grade III-IV.
Interestingly, the previously seen trend of decreased
aGVHD in more recent years documented by the
day 1100 aGVHD rates was no longer present at 6
months post-HCT. The rate of aGVHD was not af-
fected by disease status at transplantation, underlying
disease, cell source, or degree of HLAmatching (given
that the majority of patients were a 6/6 or 8/8 match).
The 2-year cumulative incidence of cGVHD was
50% (95% CI, 39%-61%) for the entire cohort. The
incidence was 42% (95% CI, 27%-57%) in patients
who underwent HCT in 2006-2008, compared with
68% (95% CI, 47%-88%) in those who underwent
HCT in 2002-2003 (P 5 .01). No other factors
significantly affected the incidence rate of cGVHD.DISCUSSION
RIC extends the potentially curative therapy of
HCT to older patients or those who would otherwise
be ineligible for full myeloablative therapy. We
studied a cohort of patients with high-risk advanced
hematologic malignancies who received a uniform
conditioning regimen and found that (1) RIC was
well tolerated by our heavily pretreated cohort of older
patients with advanced disease, and low HCT-CI cor-
related with low TRM; (2) our uniform RIC platform
produced successful engraftment and donor chime-
rism; (3) PFS was significantly affected by primary
disease, with superior outcomes seen in patients with
indolent and aggressive NHL; and (4) poorer outcomesoup
(95% CI) Relapse, % (95% CI) TRM, % (95% CI),
4-Year 1-Year 4-Year 1-Year
73 (28-93) 0 0 13 (0-34)
45 (21-66) 15 (2-29) 32 (9-54) 7 (0-17)
27 (5-56) 50 (19-81) 50 (19-81) 10 (0-27)
27 (13-44) 29 (15-43) 33 (17-49) 28 (14-42)
10 (1-36) 38 (0-48) 38 (7-69) 34 (4-63)
yelogenous leukemia; MDS, myelodysplastic syndrome; PFS, progression-
Table 3. Multivariate Analysis
Outcome Factor RR (95% CI) P Value
OS at 4 years Disease group
AML/MDS 1.0 <.01
Aggressive NHL 0.41 (0.19-0.89)
Indolent NHL 0.25 (0.06-1.09)
HL 0.32 (0.09-1.06)
Myeloma 1.69 (0.78-3.65)
PFS at 4 years Disease group
AML/MDS 1.00 .02
Aggressive NHL 0.49 (0.25-0.97)
Indolent NHL 0.26 (0.06-1.10)
HL 1.14 (0.49-2.63)
Myeloma 1.87(0.87-4.02)
TRM at 1 year HCT-CI
0-2 1.0 .04
3+ 2.41 (1.02-5.70)
Recipient CMV status
Negative 1.0 .03
Positive 2.71 (1.08-6.79)
RR indicates relative risk; CI, confidence interval; PFS, progression-free
survival; TRM, treatment-related mortality.
Only significant outcomes and factors are shown: Relapse at 4 years
showed no significant variables and thus is not shown. Variables of
age, sex, CD34+ cell dose, KPS, HCT-CI, CMV status, disease group,
and ATG exposure were evaluated.
Figure 3. One-year TRM by comorbidity score.
1030 Biol Blood Marrow Transplant 17:1025-1032, 2011E. D. Warlick et al.were seen in patients with myeloid malignancies, HL,
and myeloma, highlighting the need for additional
peritransplantation manipulations.
We found lowTRM even in older patients. Similar
to younger patients, high HCT-CI score and CMV-
seropositive status identified patients at higher risk.
In our cohort, the reasonable rates of severe grade
III-IV aGVHD and prompt neutrophil engraftment
with high donor chimerism at day 1100 possibly con-
tributed to the lowTRM. Interestingly, neither under-
lying hematologic malignancy nor disease stage at
transplantation (advanced vs early) had a significant
affect on TRM. These data support previous findings
suggesting that chronological age should not be the
primary determining factor for HCT eligibility [15]
and supporting the use of HCT-CI as a powerful
prognostic tool.Figure 2. Four-year incidence of relapse by disease group.The patterns of outcomes in OS, PFS, and relapse
based on underlying hematologic malignancy in our
cohort highlight important findings of this study. In
disease-specific subsets, we observed trends consistent
with the natural history of these diseases and their
potential responsiveness to RIC HCT. Patients with
indolent and aggressive NHL had promising PFS
and encouraging long-term OS despite having been
heavily pretreated and some having undergone previ-
ous autologousHCT.Our findings in patients with in-
dolent and aggressive NHL compare favorably with
other recent analyses [5,6] and are supported by
other studies suggesting that conditioning intensity is
less important for disease control in lymphomas and
may contribute more to TRM in those patients who
undergo HCT with underlying comorbidities [7,8].
Our patients with indolent NHL experienced no
relapses, perhaps demonstrating the sensitivity of this
disease to graft-versus-leukemia (GVL) reactions.
Relapses in patients with aggressiveNHLweremodest
and mainly occurred early; however, some later re-
lapses occurred at 3-4 years post-HCT, indicating no
relapse plateau in the observation period. Given that
the majority of the patients with NHL had advanced
disease at the time of HCT, these data underscore
the point that patients with these diseases might not
require myeloablative conditioning, and support the
concept that immunologic eradication of lymphoma
might be the precedent for long-term survival.
The outcomes in our patients with AML/MDS
highlight a very different natural history and respon-
siveness to GVL. Notably, all of the patients with
MDS had low a volume of blasts (\5%), and most of
the patients with AML were in CR1 or CR2 at that
time of HCT. Despite good disease control at trans-
plantation, relapse rates were substantial, and corre-
sponding PFS and OS were reduced. However, when
posttransplantation remission was obtained and main-
tained for 1-2 years, late relapse was not observed, and
extended survival was maintained. These findings sug-
gest that even with optimal disease status at transplan-
tation, GVL might not be adequate to control disease,
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patients with certain myeloid malignancies.
Numerous nonrandomized studies have addressed
the importance of conditioning intensity in patients
with myeloid malignancies, with conflicting data
reported. Some studies have suggested only a minimal
increased benefit from myeloablative conditioning in
patients undergoing HCT in CR [1-3], some have
suggested that myeloablative conditioning is important
for disease control when undergoing HCT with
active disease [4], and still others have suggested that
myeloablative conditioning is optimal even in patients
in CR or with\5% blasts [16]. Despite the contro-
versy, most studies in the literature stress that when
myeloablative conditioning is not an option, RIC is
a reasonable alternative that might be associated with
slightly higher rates of relapse that are frequently offset
by reduced TRM. Comparing these trials is challeng-
ing due to heterogeneous patient populations, varying
disease burden at transplantation, diversity in the de-
gree of conditioning intensity, and varying follow-up.
Randomized trials addressing this question are crucial
and are currently in development. Although signifi-
cant, our 4-year relapse rate of 33% is comparable to
rates cited in other studies (21%-61% [1,4,17,18])
and underscores the need for therapeutic adjustments
before and/or after HCT in patients with myeloid
malignancies.
The rates of severe aGVHD and cGVHDwere ac-
ceptable and comparable to those reported in previous
series [4,5,19]. Interestingly, we observed a decrease in
day 1100 aGVHD and cGHVD rates in more recent
years (2006-2008 comparedwith 2002-2003). Although
supportive care measures did not change significantly
between these two periods, and all patients were
treated with a uniform conditioning regimen platform,
MMF dosing increased from 2 g/day in 2002-2003 to
3 g/day in 2005. ATG use also increased slightly in
the 2004-2005 and 2006-2006 periods, possibly due
to more defined criteria for use and a slight increase
in the number of patients with MDS who underwent
HCT during that period. Both MMF dosing and
ATG use possibly could explain the decreases in day
1100 aGVHD and cGVHD in more recent years.
We also observed a slightly higher rate of cGVHD
in patients with indolent lymphomas, similar to
a previous report [5], which seemed to correlate with
the improved disease control in that cohort.
In summary, our platform of RIC was well toler-
ated in elderly patients, produced successful engraft-
ment, and yielded promising clinical outcomes in
patients with indolent and aggressive NHL, but un-
derscores the need for further antitumor approaches
in patients with AML/MDS and myeloma. Mainte-
nance therapy posttransplantation with such agents
as azacitidine or decitabine for myeloid malignancies[20,21] or rituximab for CD201 malignancies might
further improve these outcomes.ACKNOWLEDGMENTS
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